menu search

WVE / 4 Drug Stocks That More Than Doubled This Year

4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022. Read More
Posted: Dec 30 2022, 10:32
Author Name: Zacks Investment Research
Views: 111752

WVE News  

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

By Zacks Investment Research
September 29, 2023

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash

By Seeking Alpha
September 12, 2023

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 tri more_horizontal

Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor R more_horizontal

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 3, 2023

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to lo more_horizontal

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)

By Seeking Alpha
June 21, 2023

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade) more_horizontal

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 3, 2023

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.6 more_horizontal

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
March 22, 2023

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the num more_horizontal

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
February 14, 2023

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal


Search within

Pages Search Results: